Quality of life after surgery for neuroendocrine tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on assessing the quality of life (QOL) of patients who have undergone surgery for neuroendocrine tumors (NETs). It aims to gather comprehensive, multi-institutional data to better understand the post-operative experiences of these patients. The study will involve a prospective international cohort and will identify factors that influence QOL measures following surgery. By emphasizing both tumor control and quality of life, the research seeks to inform surgical decisions in the management of NETs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \>18 years old
* Diagnosis of well-differentiated grade 1 to 3 NETs via histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on SSTR-PET scan).
* Consents to surgery for resection of localized, loco-regional, or metastatic gastro-enteric (midgut) and pancreatic neuroendocrine tumor (GEP-NET).

Exclusion Criteria:

* Pre-operative diagnosis of neuroendocrine carcinoma on histopathology (biopsy) or imaging (measurable tumor on CT or MRI with avidity on FDG-PET scan and no avidity on SSTR-PET scan).
* Declines surgery.
* Unable to respond to study questionnaires (not proficient in local language).

Where it's running

• Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Study coordinator: Jessica Armah, MSc
• Email: jessica.armah@sri.utoronto.ca
• Phone: 416-480-6100

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• External validation of the TB-NET score in advanced well‑differentiated neuroendocrine tumors

  This study tests whether the TB-NET score can predict progression-free survival in adults with advanced well-differentiated gastroenteropancreatic neuroendocrine tumors or lung carcinoids who have received systemic therapy.

  Recruiting at 11 sites Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Boston, Massachusetts and 10 other locations · NCT07903532

• Ultralow-dose PET imaging of somatostatin receptor 2 (SSTR2) uptake

  This study will test whether an ultralow-dose 68Ga-Dotatate PET scan on a high-sensitivity scanner can detect SSTR2 uptake in adults with and without neuroendocrine tumors.

  Recruiting Phase 2 Nuclear Imaging Institute · Englewood, New Jersey · NCT07284589

• PRRT alone versus PRRT plus chemotherapy for gastroenteropancreatic neuroendocrine tumors

  This test sees if adding capecitabine–temozolomide chemotherapy to Lutetium‑177 DOTATATE PRRT helps adults with advanced gastroenteropancreatic neuroendocrine tumors live longer without the cancer getting worse.

  Recruiting at 2 sites Phase 3 Tata Memorial Hospital · Mumbai, Maharashtra and 1 other locations · NCT07185672

• How endocrine tumors develop resistance to alkylating chemotherapy

  This study will test whether patients with endocrine tumors who receive alkylating chemotherapy develop high tumor mutation rates and whether blood tests and imaging can detect those changes.

  Recruiting Uppsala University · Uppsala · NCT07121998

• Removal of the primary small-intestine neuroendocrine tumor versus systemic therapy alone

  This project tries to see if removing the main small-intestine neuroendocrine tumor helps people with incurable metastatic disease live longer or avoid future problems, compared with treating them with systemic therapy alone.

  Recruiting Insel Gruppe AG, University Hospital Bern · Bern · NCT06787014

• Using advanced imaging to detect small bowel neuroendocrine tumors

  This study is testing a new imaging method to see if it can better find small bowel neuroendocrine tumors in patients, helping doctors decide on the best treatment.

  Recruiting European Institute of Oncology · Milan · NCT06773624

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.